Seeking Alpha


Send Message
View as an RSS Feed
View candooman's Comments BY TICKER:

Latest  |  Highest rated
  • Valeant cries foul over Citron report [View news story]
    That business model is unsustainable. They jack up the price so high, everyone - insurance, consumers, regulators complain loudly so the politicians are pressured to come up with a law to stop them. That is not a sustainable model.

    Unfortunately, this business model kills other bio-pharma businesses who have sustainable business models as well. This kills innovation and is bad for everyone's health. Sooner or later everyone gets sick and need drugs and bio treatment. Hopefully, when that happens, a cure from a bio-pharma who spent millions in R&D is available.
    Oct 22, 2015. 12:19 PM | Likes Like |Link to Comment
  • Athersys Updates on Development Strategy in Japan [View article]
    ATHX is more likely to get approval for multistem use in Ischemic Stroke from the Japanese PMDA than the US FDA although both will use US Trial data.
    Oct 21, 2015. 12:36 PM | Likes Like |Link to Comment
  • Athersys and Chugai part ways on MultiStem development in Japan [View news story]
    What is your basis for claiming Gil strung along investors? It was an ongoing negotiations which both parties have only now ended. Both parties were negotiating to make the partnership work. Gil was negotiating hard to get a good deal and wanted to get good terms. Chugai was trying to take advantage of the supposedly 'failure' of the trial to get giveaway terms and Gil would have none of it. Now, Gil has a letter of intent with another Japanese company and in talks with others to get the terms he wants.

    I believe Gil may be even happy he got out of the Chugai deal for that frees him to get a better deal with other companies. Gil is a hard negotiator. He knows, in the end, Multistem will become a standard treatment for ishemic stroke like tPA except it will be applicable in the 16 to 36 hr time frame. This is the case ATHX is currently negotiating with the FDA, to allow ATHX to get into another trial but in the 16 to 36 hr time frame. The Data in the previous trial strongly indicated that this is where the treatment could be the most effective.
    Oct 21, 2015. 10:31 AM | 3 Likes Like |Link to Comment
  • Premarket Gainers / Losers as of 9:10 am [View news story]
    This is a disagreement over financial terms not about the effectivity of the treatment. ATHX is negotiating with another company and has an LOI to replace Chugai. I believe Multistem treatment will ultimately become a standard treatment for ischemic stroke like tPA (application limited to 3.5 hrs after stroke) but with a time frame of 16 to 36 hours.
    Oct 21, 2015. 10:14 AM | 2 Likes Like |Link to Comment
  • Justin Trudeau elected Prime Minister of Canada [View news story]
    We need a President who understand economics, profit making, good deal making and unbeholden to special interests and lobbyists, understand military might and patriotic. You guessed it, we need Trump.
    Oct 20, 2015. 11:03 AM | Likes Like |Link to Comment
  • VW outlines changes to diesel emissions technology [View news story]
    This is short on details. Will the new system keep the power and economy performance the same as the old one? Will the customer have to load urea in a separate tank ans they gas up?
    Oct 13, 2015. 11:07 AM | Likes Like |Link to Comment
  • Addressing A Major Public Need: The Ocata Preclinical Pipeline, Part 2: Platelet Production [View article]
    Oct 2, 2015. 09:06 AM | 1 Like Like |Link to Comment
  • Addressing A Major Public Need: The Ocata Preclinical Pipeline, Part 2: Platelet Production [View article]
    Call the short, comprehensible and very informative articles a welcome change. You are providing answers to many of my questions and I love it! Thank you Dr Hartman, please keep 'em coming.
    Oct 2, 2015. 09:05 AM | 6 Likes Like |Link to Comment
  • A Possible Cure For Blindness: The Ocata Preclinical Pipeline- Photoreceptor Progenitors [View article]
    Zach, we OCAT followers cannot thank you enough for publishing your articles. After the attempted takedown of OCAT by Mako Research, you are a great relief!

    Thanks again. Two great articles and more coming, wow!
    Sep 30, 2015. 12:05 PM | 15 Likes Like |Link to Comment
  • Light At The End Of The Tunnel For Lightbridge [View article]
    LTBR just concluded the deal for their fuel to be tested in a running reactor in Norway. This is to show that the design of the fuel is sound and materials used are what they should be in actual reactor service. This test will take two years and we do not know if there will be without glitches and successful. Until then, investors are putting their money somewhere else to get returns today.

    The current management is so slow in moving. They should have had this fuel tested and approved by the NRC today. 5 years ago they said they were ready for the actual test but nothing happened. The price reflects the poor quality of LTBR management.
    Sep 29, 2015. 04:31 PM | 1 Like Like |Link to Comment
  • The Drug Carry Trade: Valeant's Massively Leveraged Long-Short Strategy Is About To Unwind [View article]
    Let us see if the Republican chairman agrees to send this letter. If he refuses, then we can assume the Pharma lobby got to him to protect their interest. The Valeant CEO, a Canadian cannot be subpoenad by US Congress. They can force him to testify by threatening him and his executives by barring them from entering the US and arrested if they did. The SEC can open an anti-trust case against them and then ask them to testify. Valeant cannot refuse the SEC.
    Sep 29, 2015. 02:32 PM | 3 Likes Like |Link to Comment
  • Ocata to Present at Ladenburg Thalmann 2015 Healthcare Conference [View article]
    I just clicked on the link and the article comment section is not there. The header above the article indicates there are 103 comments.... which I would like very much to read.
    Sep 24, 2015. 07:43 PM | Likes Like |Link to Comment
  • Ocata to Present at Ladenburg Thalmann 2015 Healthcare Conference [View article]
    NOte that the Mako Research piece referred to by sunwindgo above no longer have a comment section. The 81 previous comments (99% against the article) is no longer accessible.

    Who removed them, Mako? Is SA aware of this? If it was removed with SA approval, we have a big problem. It is called market manipulation. I would advice SA not to participate in it, it is illegal. SA should put back the Comments or take out the article completely or risk being a sued.
    Sep 24, 2015. 12:34 PM | Likes Like |Link to Comment
  • Ocata: Dilution Imminent, SEC Investigation Potentially Underway, Office Appears Empty, Price Target $0.00 [View article]
    Thanks Mako Research for your blog. I noticed you did not disclose if you own shares or have shorted the shares before you issued this blog. I went to the top and to the end of your article a few times and I did not see ANY DISCLOSURES, please explain.

    I want to thank you profoundly for your blog. The last time this stock went down to $3.02 on Aug 17, I missed buying. On Sept 3 it reached $4.67 ($5.11 on Sept 21). Had I not missed buying, then selling on Sept 3, I would have made a 54% profit. I hope, with your blog, the stock will go down in the low $3's again and then I can buy a lot. So, I am hopeful, so hopeful I am thanking you in advance.
    Sep 23, 2015. 12:39 PM | 3 Likes Like |Link to Comment
  • Sirius Announces Extension Of Agreement With Toyota [View article]
    It remains to be seen if the other car manufacturers (Acura, BMW, Honda, Hyundai, Infiniti, Lexus, Nissan ) follow Toyota's lead. If they do, then we will see the revenue blossom.
    Sep 21, 2015. 07:20 PM | 3 Likes Like |Link to Comment